Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Publication of HN2010001319ApublicationCriticalpatent/HN2010001319A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
SE DESCRIBE UNA ANTAGONISTA DEL RECEPTOR OPIOIDE KAPPA SELECTIVO UTIL PARA TRATAR LA ABSTINENCIA Y ANSIEDAD POR TRASTORNO DE USO DE ALCOHOL ETILICO, Y/O DEPRESION, O ESQUIZOFRENIA COMO CONDICIONES CO-PATOLOGICAS INDEPENDIENTES.AN ANTAGONIST OF THE USEFUL SELECTIVE KAPPA OPIOID RECEIVER IS DESCRIBED TO TREAT ABSTINENCE AND ANXIETY DUE TO THE USE OF ETHYL ALCOHOL, AND / OR DEPRESSION, OR SCHIZOPHRENIA AS INDEPENDENT CO-PATHOLOGICAL CONDITIONS.
Compounds derived from spiropiperidine-methylbenzyloxyphenyl, activators of the rpg-40 receptor; pharmaceutical composition comprising them; and use of the compound to treat diabetes.
Crystalline compound hydrate of agomelatine hydrobromide; compound preparation method; pharmaceutical composition; use of the compound to treat sleep disorders, stress, anxiety, major depression, schizophrenia, among others.
2-AMINO-9- [4-4 (4-METOXI-PHENOXI) -PIPERIDIN-1-IL] -4-PHENYL-INDENO [1,2-D] PRIMIDIN-5-ONA AND ITS USE AS A RECEIVER ANTAGONIST OF ADENOSINA A2A HIGHLY SELECTIVE